linjc16/ctgov huggingface dataset:
Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment

Study Overview
=================
Brief Summary
-----------------
The use of Indocyanine green diagnostic dye will identify areas of vascular leakage which will provide more effective laser treatment by targeting these specific areas.

Detailed Description
-----------------
The Early Treatment of Diabetic Retinopathy Study showed that early treatment of Clinically Significant Macular Edema (CSME) with focal and grid laser preserved vision in diabetic patients. Indocyanine Green angiography, which was not available at the time of the Early Treatment Diabetic Retinopathy Study (ETDRS), is now standard-of-care for diagnostic evaluation of the choroidal circulation and is routinely done in combination with Fluorescein angiography for a more complete visualization of retinal pathology. Simultaneous examination of both retinal and choroidal circulation allows for identification of microaneurysms that are hyperfluorescent both on Fluorescein angiography and Indocyanine green angiography. Such microaneurysms are sites of increased vascular leakage and represent a means for providing more effective laser treatment by targeting these areas directly with focal laser.

Official Title
-----------------
The Use of Fluorescein-Indocyanine Green Angiography in Patients With Diabetic Macular Edema to Identify Areas of Increased Leakage and Provide Targeted Focal Laser Treatment.

Conditions
-----------------
Macular Edema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meets criteria for Clinically Significant Macular Edema Microaneurysms hyperfluorescent Exclusion Criteria: Increase intraocular pressure Intraocular inflammation Retinal detachment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary objective is to assess the effectiveness of FA-ICG guided focal laser therapy for the treatment CSME by means of serial FA-1CGs before and every 3 months after treatment. | Visual Acuity will be measured by using the Early Treatment Diabetic Retinopathy Study. (ETDRS) Macular volume will be measured by Optical coherence tomography. | 3 months |
Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the postprandial glycaemic, insulinaemic and appetite responses to porridge made with oats processed differently.

Official Title
-----------------
Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge

Conditions
-----------------
Postprandial Glycaemia,, Postprandial Insulinaemia, Appetite

Intervention / Treatment
-----------------
* Drug: Test meal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Aged 18-40 years Exclusion Criteria: Food allergies Metabolic disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pinhead oat porridge<br> | Drug: Test meal<br>* Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate<br>|
| Experimental: Rolled oat porridge<br> | Drug: Test meal<br>* Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood glucose |  | Measured at baseline, 15, 30, 45, 60, 90 and 120 min after ingestion of a test meal | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma insulin |  | Measured at baseline, 15, 30, 45, 60, 90 and 120 min after ingestion of a test meal | 
| Subjective appetite ratings | Measured by a visual analogue scale (VAS) | Measured at baseline, 15, 30, 45, 60, 90 and 120 min after ingestion of a test meal |
Reliability of Hand Held Dynamometer for Assessing Isometric Lumbar Muscle Strength in Asymptomatic Healthy Population

Study Overview
=================
Brief Summary
-----------------
To determine intra-rater and inter-rater reliability of hand held dynamometer for assessing isometric lumbar

Detailed Description
-----------------
After being informed about the study and potential risks, all participants given informed consent underwent a 1-week screening period to determine eligibility for study entry. Two raters assessed isometric strength of lumbar flexor and extensor muscles, by a hand-held dynamometer. Strength was measured and recorded by each of the two raters and re-assessed after a week.

Official Title
-----------------
Reliability of Hand Held Dynamometer for Assessing Isometric Lumbar Muscle Strength in Asymptomatic Healthy Population

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: MicroFET 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between twenty one to twenty five years Exclusion Criteria: subjects with the history of acute, subacute or chronic low back pain, history of trauma, neurological disorders, spinal surgery, lumbar spine pathology were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Rater 1<br>Rater 1 | Device: MicroFET 2<br>* Lumbar Flexor and Extensor Strength Measurement<br>|
| Active Comparator: Rater 2<br>Rater 2 | Device: MicroFET 2<br>* Lumbar Flexor and Extensor Strength Measurement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hand held dynamometer | Muscle Strength | 2 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Reliability, Lumbar region, Muscle strength dynamometer
Conventional Versus Automated Measurement of Blood Pressure in the Office (The CAMBO Study)

Study Overview
=================
Brief Summary
-----------------
To determine if the use of automated office blood pressure readings can improve management of systolic hypertension in routine clinical practice. Automated office SBP recordings in routine clinical practice using the BpTRU device will reflect more accurately the mean awake ambulatory systolic BP than will manual BP readings taken with conventional mercury sphygmomanometry. This should lead to improvements in the management of systolic hypertension with optimization of drug therapy in practices using the BpTRU device.

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Device: BpTRU
* Device: Conventional mercury sphygmomanometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both treated and untreated patients with systolic hypertension under routine FP care For untreated patients, routine office SBP as measured by the patient's FP at the last routine office visit using a mercury device must have SBP ≥ 160 mmHg and DBP <= 95 mmHg For patients already receiving antihypertensive therapy, the last routine office BP as measured by the patient's FP using mercury sphygmomanometry must be SBP ≥ 140 mmHg and DBP <= 90 mmHg Exclusion Criteria: Presence of target organ damage such as MI, stroke, and serum creatinine twice normal Diabetes mellitus treated with insulin or oral hypoglycemic therapy Secondary hypertension Participation in another research study involving measurement of BP Patient's insistence on using self BP measurement outside of the study Any conditions or circumstances which might preclude the successful completion of the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: BpTRU|nan|
|Device: Conventional mercury sphygmomanometry|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ambulatory blood pressure |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Blood Pressure, Systolic Pressure, Diastolic Pressure, Blood Pressure Monitoring, Ambulatory
Needle-X: Usability Testing of a Smartphone Application

Study Overview
=================
Brief Summary
-----------------
Mobile health interventions offer a longitudinal approach to reducing the burden of substance use disorders and may stem the rise of the opioid overdose epidemic. Smartphone applications are one of the most popular mobile phone features nationally, among patients in addiction treatment, and among criminal justice involved (CJI) patients enrolled in addiction treatment. This research conducted at Bellevue Hospital's inpatient detoxification program established attitudes and self-reported behaviors favorable to theoretical smartphone applications addressing opioid use, HIV, and HCV prevention and management strategies. This study aims to assess the feasibility and usability of a smartphone application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.

Official Title
-----------------
Needle-X: Usability Testing of a Smartphone Application

Conditions
-----------------
Opioid Dependence

Intervention / Treatment
-----------------
* Behavioral: Smartphone Application


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fluent in spoken and written English; Meets or has previously met DSM-5 criteria for current opioid use disorder, of at least moderate severity; Owns or has owned a smartphone Exclusion Criteria: Any patient who does not meet the inclusion criteria as above, is clinically unstable per the unit admitting physicians, refuses to participate in the study, or is cognitively impaired.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Needle X<br>Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City. | Behavioral: Smartphone Application<br>* App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of Needle-X application | number of patients enrolled, as this study will include a single interaction, at which point the patient will no longer be part of the study. | 12 Months |
Risk Factors and Treatment Outcome of Oncology Children Hospitalized in the Intensive Care Unit Due to Sepsis

Study Overview
=================
Brief Summary
-----------------
Children treated with intensive chemotherapy are at increased risk for life-threatening infections (sepsis). As the survival of oncology patients increased with the use of aggressive treatment protocols, there was also an increase in the need for hospitalization in intensive care units (ICU) due to sepsis.Several prognostic factors are known to affect the survival of these patients, including the number and type of damaged systems, the type of oncology disease and the duration of neutropenia. With the development of the treatment of ICU, the survival of the oncology patients hospitalized for sepsis has also increased. We will collect demographic details, details of their oncology and infections, laboratory tests and imaging. The goal is to identify prognostic factors in oncologic children hospitalized in ICU due to sepsis, as well as clinical and laboratory parameters that characterize this group of patients.

Official Title
-----------------
Retrospective Study: Risk Factors and Treatment Outcome of Oncology Children Hospitalized in the Intensive Care Unit Due to Sepsis

Conditions
-----------------
ICU, Oncologic Complications and Emergencies, Sepsis, Childhood Cancer

Intervention / Treatment
-----------------
* Other: ICU treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treatment in the hemato-oncology for cancer Admission to the ICU in SCMCI between 2008-2018 because of sepsis during chemotherapy Exclusion Criteria: Admission to the ICU more than 3 month after last chemotherapy or 1 year after SCT

Ages Eligible for Study
-----------------
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: ICU treatment|any treatment available by ICU|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival | survial status 30 day after release from the ICU | 30 day |
An Investigational Drug in Patients With Osteoarthritis (0663-073)

Study Overview
=================
Brief Summary
-----------------
This study was conducted to assess the safety and tolerability of an investigational drug and to evaluate its effectiveness in the treatment of osteoarthritis of the hip or knee in both men and women.

Detailed Description
-----------------
The duration of treatment is 12 weeks.

Official Title
-----------------
A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 2)

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: MK0663, etoricoxib
* Drug: Comparators: ibuprofen and placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with osteoarthritis of the hip or knee who use current approved medication (nonsteroidal anti-inflammatory drugs (NSAIDs)) or tylenol to treat the symptoms of their osteoarthritis. Patients taking NSAIDs are required to discontinue using these drugs and their symptoms must become worse. Exclusion Criteria: Patients with certain medical conditions may not be allowed to participate. These conditions will be reviewed with the study physician.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0663, etoricoxib|nan|
|Drug: Comparators: ibuprofen and placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC VA 3.0 pain subscale, WOMAC VA 3.0 physical function subscale, and Patient Global Assessment of Disease Status Scale. Efficacy data collected at Weeks 2, 4, 8, and 12. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Global Assessment of Response to Therapy, Investigator Global Assessment of Disease Status, Womac VA 3.0: Stiffness, Overall Average Score and Overall Subscale Average. Clinical efficacy data collected at Weeks 2, 4, 8, and 12. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arcoxia
Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19)

Study Overview
=================
Brief Summary
-----------------
To report on cases presented with combined endophthalmitis and orbital cellulitis as a first presentation of covid-19 infection.

Detailed Description
-----------------
This observation case series study included 5 patients referred to the Ophthalmology Department, Minia University with severe ophthalmic manifestations in the form of combined endophthalmitis and orbital cellulitis. On doing the work-up of covid-19 infection according to the recommendations of Egyptian Ministry of Health, patients proved to be infected by the novel Corona virus. In addition to the Corona work-up, all patients were subjected to full ophthalmological evaluation, ocular ultrasound and orbital CT examination.

Official Title
-----------------
Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19)

Conditions
-----------------
Endophthalmitis and Orbital Cellulitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with endophthalmitis and orbital cellulitis with covid-19 Exclusion Criteria: Patients without endophthalmitis and orbital cellulitis. Patients with endophthalmitis and orbital cellulitis not having covid-19 infection.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Combined Endophthalmitis and Orbital Cellulitis in patients with Novel Coronavirus Disease (COVID-19) | highlight the occurrence of combined endophthalmitis and orbital cellulitis in patients with novel Coronavirus Disease (COVID-19) | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endophthalmitis, orbital cellulitis, covid-19
Measure Cardiac Output Using Ultrasound Dilution in Mechanically Ventilated Children

Study Overview
=================
Brief Summary
-----------------
The measurement of cardiac output (CO) and hemodynamic pressures are vital for proper management of severely hemodynamic compromised patients. A new ultrasound dilution method (COstatus) for cardiac output measurement has been developed.

Detailed Description
-----------------
The thermodilution technique with a pulmonary artery catheter has been the standard in adult patients for cardiac output measurement. However, using pulmonary artery catheter remains a major clinical problem in children due to technical and size constraints. COstatus measures changes in blood ultrasound velocity in an extracorporeal AV loop caused by body-temperature isotonic saline injected into the central vein and calculates cardiac output derived from a dilution curve.

Official Title
-----------------
Investigation of the Reliability to Measure Cardiac Output by a New Ultrasound Dilution Method in Mechanically Ventilated Children After Pediatric Cardiac Surgery

Conditions
-----------------
Post Cardiac Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children <15 kg admitted to pediatric cardiac surgery for corrective surgery and mechanically ventilated were eligible for the study if parents provided informed consent. Exclusion Criteria: Children with known significant tricuspid or mitral valve regurgitations or if it is detected by the preoperative transesophageal echocardiographic examination. Children with persistent severe arrhythmias. Children with remaining intracardiac shunts after surgery, which may adversely affect the measurement.

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of cardiac output by a new ultrasound dilution method in mechanically ventilated children after pediatric cardiac surgery. | To compare cardiac outputs measured with this new ultrasound dilution method with flowmetry (perivascular probe) using ultrasound transit time measured directly on the aorta in children < 15 kg of weight. Also to assess reliability of COstatus measurements in pediatric patients. | Measurements are made during a patient's stay with insitu catheters. The expected average stay is 3-4 days. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac output, Perivascular Probe